Novartis earnings, tech stocks maintain STOXX 600's record winning streak
By Nikhil Sharma (Reuters) -European shares reached a record high on Friday, led by technology and healthcare stocks, as ...
FiercePharma15h
Novartis' Kisqali off to 'very rapid' launch in early breast cancer, CEO says. Can it keep up the momentum?
One of the most important launches for Novartis in recent years is off with a bang. | One of the most important launches for ...
Novartis Expects Further Profit, Sales Growth Despite Competition Threat
The pharma major beat analysts’ expectations in the fourth quarter of 2024, despite looming competition for its top heart ...
Novartis CEO says U.S. exit from global health programmes to affect millions
The American CEO of Swiss drugmaker Novartis on Friday warned that the United States' exit from the World Health Organization ...
Novartis Q4: Earnings Beat Estimates, CEO Dismisses Entresto Patent Expiration Worries
Novartis reported strong Q4 earnings and sales growth, with CEO Narasimhan reportedly downplaying concerns over Entresto's ...
Novartis Q4 Core EPS Beats Market, Hikes Dividend; Sees Growth In FY25; Stock Up
Swiss drug-major Novartis AG reported Friday weak net earnings in its fourth quarter on the absence of prior year's significant gain ...
FierceBiotech23h
Novartis missed the PD-1 boat. Will it catch the bispecific wave?
After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. | The rising class of bispecifics ...
FiercePharma3d
Novartis' first Super Bowl ad aims to 'create a movement' with breast cancer awareness blitz
To direct more attention toward the importance of regular breast cancer screenings, Novartis is taking to one of television’s biggest stages. | To direct more attention toward the importance of ...
Novartis reports Q4 core EPS $1.98 vs. $1.53 last year
Reports Q4 revenue $13.2B vs. $11.4B last year. Vas Narasimhan, CEO of Novartis (NVS), said: “In our first full year as a pure-play innovative ...
Novartis has cash for a big pharma deal—but here’s why it’s not buying
Novartis chief executive says large pharma deals usually don't pay off. But the company remains interested in bolt-on ...